Medtech
From University Labs to Market: 5 Medtech Spinouts
DealBio tracks early-stage medtech startups across Europe and North America. These 5 are turning university research into products through spinout formation, technology transfer and early commercial validation.
- University Spinouts
- Technology Transfer
- Medical Devices
- Academic Founders
Universities can produce the science, prototypes and patents behind new devices, but a spinout has to rebuild that work around manufacturing, regulation, clinical use and a repeatable business model.
The startups below show that transition across interventional radiology, home cardiac monitoring, neurorehabilitation, sweat diagnostics and dialysis technology.
At a Glance
- LaNua MedicalIreland2024University College Dublin
- PrecorDxNetherlands2023UMC Utrecht
- SkaaltecSwitzerland2026ETH Zurich
- DXcreteNetherlands2025Eindhoven University of Technology
- M3NephronNetherlands2025University of Twente
Developing a vascular device to block blood flow while preserving catheter access.
- Country
Ireland- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why LaNua Medical stands out
LaNua Medical is a University College Dublin spin-out built from an Enterprise Ireland Commercialisation Fund research project. Its ECORE device translates academic engineering and interventional radiology, minimally invasive procedures guided by medical imaging, into a new approach to embolization.
The startup raised a €6 million seed round co-led by Elkstone and Atlantic Bridge and was named the 2025 NovaUCD Spin-out of the Year.
What LaNua Medical is building
ECORE is an umbrella-shaped vascular device deployed inside a blood vessel to block flow at a selected point while preserving a central channel for guidewires and catheters.
That architecture is designed to let interventional radiologists keep access to vessels beyond the occlusion, addressing a practical limitation of conventional coils, plugs and particles.
02
PrecorDx
Developing a wearable radio-frequency sensor for home heart-function monitoring.
- Country
Netherlands- Founded
- 2023
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why PrecorDx stands out
PrecorDx is a UMC Utrecht spin-off commercializing university-developed radio-frequency sensing for chronic heart failure. Co-founder Nico van den Berg is a UMC Utrecht professor and co-founder of the spin-off, while the core sensing method is patent-backed.
The startup has received NWO Take-off and Health~Holland support and has produced human-study results, giving the academic technology an early clinical translation path.
What PrecorDx is building
PrecorDx is developing a wearable radio-frequency sensor that measures cardiac and respiratory motion from the chest without repeated blood draws or an implanted sensor.
The goal is to monitor heart-failure patients more frequently at home and identify changes associated with deterioration before they become severe enough to require hospital care.
03
Skaaltec
Developing a wearable nerve-stimulation system to improve arm recovery after stroke.
- Country
Switzerland- Founded
- 2026
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why Skaaltec stands out
Skaaltec has peer-reviewed feasibility data for SmartVNS. In a JNER study, the system triggered stimulation on 50.4% of functional movements versus 23.4% with therapist triggering, while maintaining similar precision.
A separate 2026 Journal of Neuroscience study found that movement-paired ear stimulation selectively activated motor circuitry. The startup has also secured a CHF 150,000 InnoBooster grant and repeat Future of Health support.
What Skaaltec is building
SmartVNS pairs a wrist motion sensor with non-invasive stimulation of a vagus nerve branch, part of a major nerve linking the brain with the heart, lungs and digestive system, in the outer ear. When the sensor detects a functional arm movement, the system automatically triggers a short stimulation pulse.
The wearable is designed to pair stimulation with more rehabilitation movements without requiring a therapist to trigger every pulse, supporting use in both clinic and home settings.
04
DXcrete
Developing a sweat-sensing patch for frequent kidney-function monitoring.
- Country
- Netherlands
- Founded
- 2025
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why DXcrete stands out
DXcrete builds on peer-reviewed microfluidics, technology for handling tiny liquid volumes in small channels, from Eindhoven University of Technology. A 2024 Lab on a Chip study demonstrated on-body transport of approximately one-nanolitre sweat droplets at resting sweat rates, validating the core fluid-handling approach behind the wearable.
The startup has licensed sweat-sensing IP from Philips and secured €185,000 through NWO Faculty of Impact, while moving precision glass components toward pilot production.
What DXcrete is building
DXcrete is developing BEA, a skin-worn patch that collects sweat from individual glands and uses electrowetting, electrically controlled movement of tiny liquid droplets, to move them to an on-chip creatinine sensor.
The system is designed to work while the wearer is at rest, creating a route toward more frequent kidney-function measurements outside scheduled laboratory testing.
Developing dialysis filters that improve toxin removal and regenerate dialysate.
- Country
- Netherlands
- Founded
- 2025
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why M3Nephron stands out
M3Nephron builds on University of Twente membrane research tested in human plasma. Its mixed-matrix membranes, filters that combine a membrane with adsorptive particles, removed two to three times more protein-bound toxins, waste molecules attached to blood proteins that conventional dialysis removes poorly, than conventional dialysis membranes.
The core technology is protected by a granted US patent, while Startupfonds Overijssel and imec.istart.nl have backed commercialization of the university spin-off.
What M3Nephron is building
M3Nephron is developing mixed-matrix membrane dialyzers that combine filtration and adsorption, binding selected molecules to a material, to remove toxins that conventional hemodialysis handles poorly.
The same membrane architecture is designed to regenerate dialysate, the fluid used during dialysis to remove waste from blood, for reuse, reducing water and fluid requirements and supporting more compact home and portable dialysis systems.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
University spinouts are converting research assets into operating companies
Each startup begins with a substantial academic asset: university-developed IP, published evidence or technology created by founders who know the underlying science first-hand. That gives these teams a stronger starting point as they turn research into products for hospitals, clinicians and patients.
The investment case becomes stronger as those research assets are paired with the capabilities needed to build a scalable medtech business. Across the five startups, that already includes seed financing, licensed or patented IP, product engineering, pilot manufacturing, human or peer-reviewed validation and early routes into clinical markets.
Methodology
DealBio selected these startups from its coverage of early-stage health and longevity startups, focusing on medtech ventures with a documented university or academic spinout origin and a clear path from research asset to commercial product. The selection covers five different clinical workflows to avoid grouping multiple versions of the same device model.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.